Brock L. Schweitzer

832 total citations
27 papers, 538 citations indexed

About

Brock L. Schweitzer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Brock L. Schweitzer has authored 27 papers receiving a total of 538 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Brock L. Schweitzer's work include Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Treatments and Mutations (9 papers) and Ferroptosis and cancer prognosis (6 papers). Brock L. Schweitzer is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Treatments and Mutations (9 papers) and Ferroptosis and cancer prognosis (6 papers). Brock L. Schweitzer collaborates with scholars based in United States, Canada and Austria. Brock L. Schweitzer's co-authors include Rodney P. DeKoter, David R. Hout, Robert S. Seitz, Stephan W. Morris, Kelly J. Huang, Brian Z. Ring, Jennifer A. Pietenpol, Brian D. Lehmann, Patrick M. Boland and Tanios Bekaii‐Saab and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Brock L. Schweitzer

24 papers receiving 528 citations

Peers

Countries citing papers authored by Brock L. Schweitzer

Since Specialization

Citations

This map shows the geographic impact of Brock L. Schweitzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brock L. Schweitzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brock L. Schweitzer more than expected).

Fields of papers citing papers by Brock L. Schweitzer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brock L. Schweitzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brock L. Schweitzer. The network helps show where Brock L. Schweitzer may publish in the future.

Co-authorship network of co-authors of Brock L. Schweitzer

This figure shows the co-authorship network connecting the top 25 collaborators of Brock L. Schweitzer. A scholar is included among the top collaborators of Brock L. Schweitzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brock L. Schweitzer. Brock L. Schweitzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients 2022 ·Journal of Translational Medicine ·Robert S. Seitz, Michael E. Hurwitz, (unknown), Daniel Bailey, Matthew G. Varga, Brian Z. Ring, (unknown), Brock L. Schweitzer, Kimberly McGregor, Douglas T. Ross	7
2	27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study 2022 ·Clinical Lung Cancer ·David L. Saltman, Matthew G. Varga, (unknown), Nicole S. Croteau, (unknown), Amit Jain, Gregory A. Vidal, David R. Hout, Brock L. Schweitzer, Robert S. Seitz, Douglas T. Ross, David R. Gandara	2
3	Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer 2022 ·BMC Cancer ·(unknown), Amit Jain, (unknown), (unknown), (unknown), Emily J. Miller, (unknown), (unknown), Robert S. Seitz, David R. Hout, Matthew G. Varga, Brock L. Schweitzer, (unknown), (unknown), Douglas T. Ross, David R. Gandara, Gregory A. Vidal	7
4	The 27-gene IO score is associated with molecular features and response to immune checkpoint inhibitors (ICI) in patients with gastric cancer. 2022 ·Journal of Clinical Oncology ·Matthew G. Varga, (unknown), (unknown), (unknown), David R. Hout, (unknown), Kimberly McGregor, David R. Gandara, Brock L. Schweitzer	0
5	LBA12 Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial 2021 ·Annals of Oncology ·Giampaolo Bianchini, Matteo Dugo, Chiun‐Sheng Huang, Daniel Egle, B. Bermejo, Robert S. Seitz, (unknown), Claudio Zamagni, Marc Thill, A. Antón, Sofía Russo, Eva Ciruelos, Brock L. Schweitzer, Richard Greil, Vladimir Semiglazov, Balázs Győrffy, Pinuccia Valagussa, (unknown), Maurizio Callari, Luca Gianni	15
6	5 CD274 (PD-L1) gene expression and the 27-gene immuno-oncology (IO) assay are associated with efficacy to immune checkpoint inhibitor treated patients with non-small cell lung cancer (NSCLC) 2021 ·Regular and Young Investigator Award Abstracts ·(unknown), Matthew G. Varga, (unknown), Douglas S. Ross, Brock L. Schweitzer, Robert S. Seitz, Gregory A. Vidal	2
7	Association with immune checkpoint inhibitor efficacy of a 27-gene classifier in renal cell cancer. 2021 ·Journal of Clinical Oncology ·Robert S. Seitz, (unknown), Brock L. Schweitzer, David R. Gandara, Mamta Parikh, (unknown)	0
8	Validation of an immunomodulatory gene signature algorithm to predict response to neoadjuvant immunochemotherapy in patients with primary triple-negative breast cancer. 2020 ·Journal of Clinical Oncology ·Toshiaki Iwase, Lajos Pusztai, Kim Blenman, Xiaotong Li, Robert S. Seitz, (unknown), Brock L. Schweitzer, David R. Hout, (unknown), Xiang Zhang, Yichao Shen, Naoto T. Ueno	1
9	Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research 2020 ·PLoS ONE ·José Rodrigo Espinosa Fernández, Bedrich L. Eckhardt, Jangsoon Lee, Bora Lim, (unknown), Robert S. Seitz, David R. Hout, Brock L. Schweitzer, (unknown), (unknown), Ying Wang, Arvind Rao, Naoto T. Ueno	23
10	Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial 2019 ·Annals of Oncology ·John H. Strickler, Tyler Zemla, Fang‐Shu Ou, Andrea Cercek, Christina Wu, Fabiola A. Sánchez, Joleen M. Hubbard, (unknown), (unknown), Brock L. Schweitzer, Donna Niedzwiecki, Nancy E. Kemeny, Patrick M. Boland, Kimmie Ng, Tanios Bekaii‐Saab	74
11	Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue 2017 ·BMC Cancer ·Bojana Jovanović, Quanhu Sheng, Robert S. Seitz, (unknown), Stephan W. Morris, Lance R. Thomas, David R. Hout, Brock L. Schweitzer, Yan Guo, Jennifer A. Pietenpol, Brian D. Lehmann	28
12	Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer 2017 ·Cancers ·David R. Hout, Brock L. Schweitzer, (unknown), Stephan W. Morris, Tracy Tucker, (unknown), Rachel L. Skelton, Frank B. McMahon, (unknown), Mary Lesperance, Aly Karsan, David L. Saltman	23
13	Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients 2016 ·BMC Cancer ·Brian Z. Ring, David R. Hout, Stephan W. Morris, (unknown), Brock L. Schweitzer, Daniel Bailey, Brian D. Lehmann, Jennifer A. Pietenpol, Robert S. Seitz	52
14	Abstract 1930: The unknown piece of the pie: Molecular markers in triple-negative lung cancer. 2013 ·Cancer Research ·Brock L. Schweitzer, (unknown), (unknown), Rachel L. Skelton, (unknown), Liquan Xue, Stephan W. Morris, David R. Hout	1
15	Cutting Edge: K63-Linked Polyubiquitination of NEMO Modulates TLR Signaling and Inflammation In Vivo 2008 ·The Journal of Immunology ·(unknown), Zhao‐Hui Wu, William C. Florence, Vrajesh V. Parekh, Maria P. Arrate, Steven Pierce, Brock L. Schweitzer, Luc Van Kaer, Sebastian Joyce, Shigeki Miyamoto, Dean W. Ballard, Eugene M. Oltz	38
16	Transgenic expression of Spi‐C impairs B‐cell development and function by affecting genes associated with BCR signaling 2008 ·European Journal of Immunology ·Xiang Zhu, Brock L. Schweitzer, Eric J. Romer, Courtney E. W. Sulentic, Rodney P. DeKoter	12
17	Reduction in PU.1 activity results in a block to B-cell development, abnormal myeloid proliferation, and neonatal lethality 2007 ·Experimental Hematology ·Isaac B. Houston, (unknown), Brock L. Schweitzer, Timothy M. Chlon, Rodney P. DeKoter	35
18	Regulation of the Interleukin-7 Receptor α Promoter by the Ets Transcription Factors PU.1 and GA-binding Protein in Developing B Cells 2007 ·Journal of Biological Chemistry ·Rodney P. DeKoter, Brock L. Schweitzer, (unknown), (unknown), Hiromi Tagoh, Constanze Bonifer, David A. Hildeman, Kelly J. Huang	45
19	Spi-C Has Opposing Effects to PU.1 on Gene Expression in Progenitor B Cells 2006 ·The Journal of Immunology ·Brock L. Schweitzer, Kelly J. Huang, (unknown), Alexander Emelyanov, Barbara K. Birshtein, Rodney P. DeKoter	27
20	Analysis of Gene Expression and Ig Transcription in PU.1/Spi-B-Deficient Progenitor B Cell Lines 2004 ·The Journal of Immunology ·Brock L. Schweitzer, Rodney P. DeKoter	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact